Diffuse large B-cell lymphoma
M Martelli, AJM Ferreri, C Agostinelli, A Di Rocco… - Critical reviews in …, 2013 - Elsevier
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid malignancy in adults
accounting for 31% of all NHL in Western Countries. Following, morphological, biological …
accounting for 31% of all NHL in Western Countries. Following, morphological, biological …
Understanding intraocular lymphomas
SE Coupland, B Damato - Clinical & experimental …, 2008 - Wiley Online Library
The purpose of this review is to describe the clinical features, pathology and molecular
biology of intraocular lymphomas, which represent a heterogenous group of malignant …
biology of intraocular lymphomas, which represent a heterogenous group of malignant …
CNS international prognostic index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP
N Schmitz, S Zeynalova, M Nickelsen… - Journal of Clinical …, 2016 - ascopubs.org
Purpose To develop and validate a risk score for relapse in the CNS in patients with diffuse
large B-cell lymphoma (DLBCL). Patients and Methods A total of 2,164 patients (18 to 80 …
large B-cell lymphoma (DLBCL). Patients and Methods A total of 2,164 patients (18 to 80 …
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial
AJM Ferreri, M Reni, M Foppoli, M Martelli… - The Lancet, 2009 - thelancet.com
Background Chemotherapy with high-dose methotrexate is the conventional approach to
treat primary CNS lymphomas, but superiority of polychemotherapy compared with high …
treat primary CNS lymphomas, but superiority of polychemotherapy compared with high …
First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an …
Purpose Primary testicular lymphoma (PTL) has poor prognosis with failures in contralateral
testis, CNS, and extranodal sites. To prevent these events, we designed an international …
testis, CNS, and extranodal sites. To prevent these events, we designed an international …
High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system …
We assessed the cerebrospinal fluid (CSF) by flow cytometry and cytology in 51 newly
diagnosed and 9 treated aggressive B-cell lymphomas at risk for central nervous system …
diagnosed and 9 treated aggressive B-cell lymphomas at risk for central nervous system …
CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in …
V Boehme, N Schmitz, S Zeynalova… - Blood, The Journal …, 2009 - ashpublications.org
One thousand two hundred twenty-two patients treated in the Rituximab with CHOP over
age 60 years (RICOVER-60) trial were examined for central nervous system (CNS) disease …
age 60 years (RICOVER-60) trial were examined for central nervous system (CNS) disease …
Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL
M Klanova, LH Sehn, I Bence-Bruckler… - Blood, The Journal …, 2019 - ashpublications.org
Central nervous system (CNS) relapse carries a poor prognosis in diffuse large B-cell
lymphoma (DLBCL). Integrating biomarkers into the CNS–International Prognostic Index …
lymphoma (DLBCL). Integrating biomarkers into the CNS–International Prognostic Index …
Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma
JL Rubenstein, J Fridlyand, L Abrey, A Shen… - Journal of clinical …, 2007 - ascopubs.org
Purpose We previously determined that intravenous administration of rituximab results in
limited penetration of this agent into the leptomeningeal space. Systemic rituximab does not …
limited penetration of this agent into the leptomeningeal space. Systemic rituximab does not …
Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high‐risk patients with diffuse large B‐cell …
JS Abramson, M Hellmann, JA Barnes… - Cancer, 2010 - Wiley Online Library
BACKGROUND: The outcome of patients with systemic diffuse large B‐cell lymphoma
(DLBCL) had improved over the past decade with the addition of monoclonal antibody …
(DLBCL) had improved over the past decade with the addition of monoclonal antibody …